SCHEMBL5372485

SCHEMBL5372485

CC1CN(CCN2CCN(C(=O)OC(C)(C)C)[C@H](Cc3ccc(Cl)cc3)C2)CC(C)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.44
NR1H3 Q13133 2/20 0.44
POLB P06746 2/20 0.43
KMT2A Q03164 5/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
VEGFA P15692 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
PARP1 P09874 1/20 0.38
MEN1 O00255 3/20 0.38
DPP4 P27487 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HDAC1 Q13547 1/20 0.37
THRB P10828 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SIGMAR1 Q99720 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372479 1.00 NR1H2 (0.44) NR1H2NR1H3POLBKMT2AALDH1A1
SCHEMBL5363572 0.89 NR1H2 (0.43) NR1H2NR1H3ALDH1A1KDM4EPARP1
SCHEMBL5363568 0.89 NR1H2 (0.43) NR1H2NR1H3ALDH1A1KDM4EPARP1
SCHEMBL5366678 0.85 NR1H2 (0.41) NR1H2NR1H3KMT2AKDM4EL3MBTL1
SCHEMBL5366671 0.85 NR1H2 (0.41) NR1H2NR1H3KMT2AKDM4EL3MBTL1
SCHEMBL5369120 0.82 NR1H2 (0.54) NR1H2NR1H3ALDH1A1KDM4EPARP1
SCHEMBL6099031 0.82 NR1H2 (0.54) NR1H2NR1H3ALDH1A1KDM4EPARP1
Hydrochloric Acid SCHEMBL5370332 0.80 POLB (0.43) POLBKMT2AALDH1A1KDM4EL3MBTL1
Hydrochloric Acid SCHEMBL5370338 0.80 POLB (0.43) POLBKMT2AALDH1A1KDM4EL3MBTL1
Hydrochloric Acid SCHEMBL5366443 0.78 RHOC (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123532-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2007-05-31 US disclosed
US-7166598-B2 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2007-01-23 US disclosed
EP-1140924-B1 PIPERAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2006-03-22 EP disclosed
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2006-01-19 US disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals PKD2, TAC3, PKD1 NR1H2 2405/4885NR1H3 3266/4885POLB 4014/4885
US-20070123532-A1 PIPERAZINE DERIVATIVES PKD2, SSTR5, IL5 NR1H2 2661/4885NR1H3 3755/4885POLB 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.